<DOC>
	<DOCNO>NCT02715570</DOCNO>
	<brief_summary>PC945 new medicine develop treatment fungal lung disease . The main purpose study investigate safety , tolerability pharmacokinetics single repeat dos PC945</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics Single Repeat Doses PC945</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>All subject ( Cohorts 1 , 2 &amp; 3 ) Male female , age 18 65 year inclusive ( time consent ) fit one follow criterion : Women childbearing potential willing able use require contraception screen 30 day receipt final dose ; Women nonchildbearing potential define amenorrhoeic permanently sterilise ; Men willing able use require contraception time first dose , 90 day receipt final dose study medication . Females negative pregnancy test screen Day 1 . Willing able adhere restriction prohibition require protocol . Signed informed consent form . Body weight ≥ 50 kg body mass index ( BMI ) within range 18 — 30 kg/m2 ( inclusive ) . Average QTcF &lt; 450 msec screen predose . Vital sign assessment within normal range Healthy Subjects ( Cohorts 1 2 ) Healthy determine physician base full medical examination . Spirometry reading ( FEV1 FVC ) ≥ 80 % predict value FEV1/FVC ratio &gt; 0.7 screening . Subjects Asthma ( Cohort 3 ) Diagnosis asthma . Positive result methacholine challenge screen visit . FEV1 &gt; 60 % predict normal value screen . Stable asthma base physician assessment screening , change therapy 12 week prior screen hospitalization visit accident emergency asthma 12 month prior screen Otherwise healthy basis full medical examination screen All subject ( Cohorts 1 , 2 &amp; 3 ) Any acute illness . Upper low respiratory tract infection within 4 week screen visit randomisation . Use prescription medication within 14 day Screening visit . Taking counter ( OTC ) medication vitamins multivitamin , within 14 day prior Screening . History regular alcohol consumption within 6 month study average weekly intake &gt; 21 unit male , &gt; 14 unit female . History drug alcohol abuse within previous 5 year . Smoker ( regular irregular ) , smoke use nicotinecontaining product ( include ecigarettes ) within 6 month prior screen smoke history ≥ 10 pack year . Positive test HIV1 &amp; 2 antibody screen . Positive prestudy hepatitis B surface antigen positive hepatitis C antibody result screen . Positive test alcohol , smoke drug abuse screen Day 1 . Received experimental drug use experimental medical device within last 3 month . Allergy active inactive ingredient study medication . Donation blood excess 500 mL within 3 month period prior dose , study participation would result blood loss excess 500 mL 3 month period . Mentally legally incapacitate . An employee Sponsor contract research organisation ( CRO ) , relative employee Sponsor CRO . Unable unwilling undergo multiple venepuncture procedure poor access vein suitable cannulation . Pregnant lactate female Healthy subject ( Cohorts 1 2 ) Any chronic illness clinically relevant abnormality identify screen medical assessment , laboratory test ECG . Subjects asthma ( Cohort 3 ) Had episode lifethreatening asthma . Presence clinically significant disease asthma , hyperresponsive airway , seasonal allergic rhinitis atopic disease . Experienced acute asthma exacerbation 12 month prior screen require hospitalisation accident emergency treatment management systemic injectable steroid . Uncontrolled , moderate severe asthma base PI assessment and/or use prohibit medication , require treatment therapy previous 12 week . History presence know condition contraindicate methacholine challenge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aspergillus specie</keyword>
	<keyword>Filamentous fungi</keyword>
	<keyword>14-alpha Demethylase Inhibitors</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Allergic Bronchopulmonary</keyword>
	<keyword>Asthma</keyword>
</DOC>